CureVac NV logo

CureVac NV

WBO:CVAC (Germany)   Ordinary Shares
€ 3.14 (-1.1%) Mar 1
At Loss
P/B:
1.19
Market Cap:
€ 708.84M ($ 768.64M)
Enterprise V:
€ 283.35M ($ 307.26M)
Volume:
15.00
Avg Vol (2M):
494.00
Also Trade In:
Volume:
15.00
At Loss
Avg Vol (2M):
494.00

Business Description

Description
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 11.1
Equity-to-Asset 0.72
Debt-to-Equity 0.07
Debt-to-EBITDA -0.15
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.22
Distress
Grey
Safe
Beneish M-Score 3.51
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 40.48
9-Day RSI 41.59
14-Day RSI 39.98
6-1 Month Momentum % -60.63
12-1 Month Momentum % -59.57

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.56
Quick Ratio 3.41
Cash Ratio 3.1
Days Inventory 49.28
Days Sales Outstanding 55.05
Days Payable 76.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3.5
Shareholder Yield % -38.33

Financials (Next Earnings Date:2024-04-25 Est.)

WBO:CVAC's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

CureVac NV Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 42.88
EPS (TTM) (€) -1.47
Beta 0.98
Volatility % 60.71
14-Day RSI 39.98
14-Day ATR (€) 0.078572
20-Day SMA (€) 3.1945
12-1 Month Momentum % -59.57
52-Week Range (€) 3.045 - 10.96
Shares Outstanding (Mil) 223.92

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CureVac NV Filings

Filing Date Document Date Form
No Filing Data

CureVac NV Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

CureVac NV Frequently Asked Questions

What is CureVac NV(WBO:CVAC)'s stock price today?
The current price of WBO:CVAC is €3.14. The 52 week high of WBO:CVAC is €10.96 and 52 week low is €3.05.
When is next earnings date of CureVac NV(WBO:CVAC)?
The next earnings date of CureVac NV(WBO:CVAC) is 2024-04-25 Est..
Does CureVac NV(WBO:CVAC) pay dividends? If so, how much?
CureVac NV(WBO:CVAC) does not pay dividend.

Press Release

Subject Date
No Press Release